Three Things We’ve Learnt From This Year’s Nobel Awards In The Sciences

While coronavirus will undoubtedly be the first thing people remember about 2020, the prominent role of science in society won’t be far behind – as I’ve written about previously.

And so it was with this year’s Nobel Prize announcements in the sciences that we were reminded of some other great achievements of our time away from the race to find a vaccine, with each of them rightly gaining a good share of media attention.  

To me, three things stood out. 

1) U.K. pedigree 

Ahead of the publication of the U.K. government’s new industrial strategy – in which science and innovation are anticipated to underpin all of the main themes – we were

Read More
Read More

2020 Life Sciences Sector Report from CLSA Shows Strong Growth in Jobs, Investments and Therapeutic Pipeline in California

SAN FRANCISCO, SACRAMENTO, SAN DIEGO, Calif. & WASHINGTON–(BUSINESS WIRE)–Oct 7, 2020–

California Life Sciences Association (CLSA), the trade association representing California’s life sciences industry, today released the 2020 California Life Sciences Sector Report, which shows that California’s life sciences sector directly employed 323,723 people, generated $191.6 billion in revenue, is projected to attract $6.5 billion in venture capital (VC) and received $4.5 billion in funding from the NIH. Produced with PwC US, the 2020 snapshot highlights the strength of California’s biomedical sector – the largest cluster in the world – as evidenced by significant increases in employment, earnings, graduating science and engineering PhDs, VC investment, and potential new drugs and medical devices in the pipeline.

Key Highlights from 2020 California Life Sciences Sector Report

  • 4.0% increase in total life sciences jobs (up more than 12,000 from prior year), with companies directly employing 323,723 Californians – the most in
Read More
Read More

Biomedical sciences researchers find new way to prevent and cure rotavirus, other viral infections — ScienceDaily

A combination of two substances secreted by the immune system can cure and prevent rotavirus infection, as well as potentially treat other viral infections that target epithelial cells, which cover body surfaces such as skin, blood vessels, organs and the urinary tract, according to researchers in the Institute for Biomedical Sciences at Georgia State University.

Rotavirus, which causes severe, life-threatening diarrhea in young children and moderate gastrointestinal distress in adults, leads to thousands of deaths in children annually, particularly in developing countries where rotavirus vaccines are only moderately effective. Rotavirus is an RNA virus that primarily infects intestinal epithelial cells.

The substances identified in the study, officially known as cytokines, are interleukin 18 (IL-18) and interleukin 22 (IL-22). IL-18 and IL-22 are produced when the body detects a protein in the whip-like appendage of bacteria.

The study, which investigated how these cytokines inhibit rotavirus infection, found when mice were treated

Read More
Read More

NSF selects Sean Jones to head Mathematical and Physical Sciences directorate | NSF

News Release 20-009

NSF selects Sean Jones to head Mathematical and Physical Sciences directorate

Sean Jones

Sean Jones will serve as head of the NSF Directorate for Mathematical and Physical Sciences.

September 29, 2020

The U.S. National Science Foundation has selected Sean Jones to serve as head of the Directorate for Mathematical and Physical Sciences.

Jones has worked as an innovator in the field of materials science; an advocate for inspiring and training the next generation of researchers and skilled workers; and a leader at NSF, committed to institutional improvements that serve the science and engineering community as well as the public. He has served with NSF for more than a decade, starting as a program director in 2009 and most recently heading the MPS Directorate as acting assistant director.

“Sean Jones’s expertise and experience as a leader both in academia and industrial research are rich perspectives that we need as we

Read More
Read More

David Whiting Named President of Comerica Bank’s Technology and Life Sciences Division

DALLAS, Sept. 22, 2020 /PRNewswire/ — Comerica Incorporated (NYSE: CMA) announced that David Whiting, Senior Managing Director of Technology and Life Sciences (TLS) Division, has been named President, TLS Division. In his role, Whiting will manage Comerica’s TLS teams in California, Massachusetts, New York, Texas, Virginia, Washington and Toronto, Canada.

Whiting, a 17-year veteran of Comerica, has served in various leadership roles within the TLS Division during his tenure. Most recently, he directed all TLS Division U.S. offices outside of California. For more than a decade he led the Dallas TLS team, as well as oversaw the Upper Midwest market, lending to venture-backed technology in various life cycles. He also has served in operating and finance capacities with a software company, as well as roles serving the lending needs of technology companies with Imperial Bank.  

“We look forward to leveraging David’s experience

Read More
Read More

TriSalus Life Sciences Lays Out Therapeutic Strategy Upon Acquisition of First Therapeutic Candidate

  •  Initiating clinical trials to evaluate investigational toll-like receptor 9 agonist, SD-101, in patients with uveal melanoma liver metastases followed by three additional indications.

  • Aspiring to overcome the challenges of treating patients with solid tumors through our multi-pronged approach to stimulate the immune system and deliver immuno-oncology therapies directly to the site of the disease, with the goal of improving the therapeutic index

  • Working to redefine the treatment of hard-to-treat solid tumors in the liver or pancreas by combining TriSalus’ proprietary FDA cleared intravascular, regional drug delivery technology for liver and pancreatic infusion with investigational SD-101 and standard of care therapy

TriSalus Life Sciences (TriSalus), an emerging immuno-oncology company committed to transforming outcomes for patients with solid tumors, announced today its therapeutic clinical development strategy following the successful acquisition of SD-101, an investigational IND-ready immunotherapy, from Dynavax Technologies on August 3, 2020.

SD-101 is an investigational toll-like receptor 9 (TLR9) agonist

Read More
Read More